New Female Arousal Drug ‘Lybrido’ Will Be Released In 2016, Drugs Trials To Be Conducted Shortly

The first female arousal drug called Lybrido will be in the market by 2016, according to a cover story in the New York Times.

In differentiating between Viagra and this arousal drug, Lybrido, Daniel Bergner writes, “A female-desire drug would be something else. It would reach into the psyche.”

While one can cure sexual dysfunction for a man by merely changing the blood flow rate to the penis, it’s more complex for a woman and where increasing blood flow to the vagina is just one aspect but also requires a few additional effects on a woman’s mind.

In other words, the perfect drug will increase levels of dopamine and reduce levels of serotonin, where the former will induce feelings of lust and impulsiveness while the latter contributes to inhibition and calmness.

There’s no doubt that as trials for this drug gets underway that the debate, for the fear of a sexually aggressive woman, will become the subject of heated discussion sooner or later.

Speaking of these trials, the participants will be women who have been in long-term relationships. Single women will not be part of these trials as new lovers tend to “bring surges of lust”. This is because these feelings of lust rapidly drop for women in long-term relationships and who live with their partners.

Interestingly, this drug was created by a male scientist who suffered heartbreak after a long-term relationship of his ended in his quest to understand the female psyche.

Despite the positive reaction, several critics are pointing out the effects of this drug which could lead to societal splintering, thanks to female excesses, when it is used by women in the future.